Immediate Impact

3 by Nobel laureates 56 standout
Sub-graph 1 of 24

Citing Papers

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Synthesis of chitosan/PVA/copper oxide nanocomposite using Anacardium occidentale extract and evaluating its antioxidant, antibacterial, anti-inflammatory and cytotoxic activities
2025 Standout
1 intermediate paper

Works of Joe Healy being referenced

Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis
2024
Monoamine Oxidases: Certainties and Uncertainties
2004

Author Peers

Author Last Decade Papers Cites
Joe Healy 174 15 41 80 59 7 346
David R. Patek 221 4 28 77 41 8 360
John V. Burba 149 2 12 65 74 11 350
Erin M. G. Allen 178 10 31 72 17 6 407
E. Philip Jesudason 145 6 18 55 58 13 396
Alsiddig Osama 193 22 8 65 38 14 351
Bryan Johnson 164 19 8 51 22 13 354
Xiu Zhu Sun 285 4 14 22 55 12 411
F. Manganaro 146 6 31 95 8 12 328
Deyamira Matuz‐Mares 186 15 11 58 16 15 375
Nidhi Kaur Bhatia 127 71 21 35 11 330

All Works

Loading papers...

Rankless by CCL
2026